Premium
Expression of class I histocompatibility antigens in transitional cell carcinoma of the urinary bladder in relation to survival
Author(s) -
Levin I.,
Klein T.,
Goldstein J.,
Kuperman O.,
Kanetti J.,
Klein B.
Publication year - 1991
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19911215)68:12<2591::aid-cncr2820681212>3.0.co;2-l
Subject(s) - transitional cell carcinoma , medicine , histocompatibility , immunoperoxidase , human leukocyte antigen , urinary bladder , antigen , major histocompatibility complex , cystectomy , carcinoma , bladder cancer , oncology , cancer , immunology , pathology , antibody , monoclonal antibody
The expression of class I histocompatibility antigens (HLA) in transitional cell carcinoma of the bladder was studied by the immunoperoxidase technique and correlated with tumor differentiation and survival. Tumors of 33 patients who underwent cystectomy were examined; 57% of the tumors expressed HLA class I antigens. Positive expression was observed in 5 of 6 cases with Grade 1 tumors, 8 of 13 with Grade 2, and 6 of 14 with Grade 3. The 5‐year survival was significantly better in patients with HLA class I‐positive tumors (74%) compared with those with negative tumors (36%, P < 0.05). The expression of HLA class I on tumor cells may serve as a target for the immune response and control the metastatic potential of the tumor. These results suggest that HLA class I expression in bladder carcinoma is a prognostic indicator that should be considered in treatment planning. Cancer 68:2591–2594, 1991.